布地奈德+沙丁胺醇雾化吸入联合口服孟鲁司特治疗婴幼儿喘息性支气管炎的效果

Effect of Budesonide combined with Salbutamol inhalation combined with Montelukast in the treatment of infants with asthmatic bronchitis

目的研究并探讨婴幼儿喘息性支气管炎门诊雾化吸入治疗过程中采用孟鲁司特口服治疗的临床效果。方法选取2013年1月~2016年10月我院儿科门诊收治的100例婴幼儿喘息性支气管炎患儿作为研究对象,采取计算机单盲随机分组方法分为两组,对照组50例患儿接受布地奈德+沙丁胺醇雾化吸入治疗,观察组50例患儿在对照组治疗基础上加用孟鲁司特口服治疗。比较两组喘息性支气管炎患儿的临床治疗效果、症状缓解时间、门诊治疗时间、不良反应发生率。结果观察组患儿的治疗总有效率(96%)明显高于对照组患儿(80%),差异有统计学意义(P<0.05);观察组患儿的喘息[(4.10±1.85)d]、咳嗽[(2.01±0.96)d]、哮鸣音[(4.59±1.94)d]等症状缓解时间及门诊治疗时间(6.13±1.72 d)均明显短于对照组[(6.73±2.42)、(3.36±1.28)、(7.23±2.60)、(8.49±2.38)d],差异有统计学意义(P<0.05);观察组患儿的不良反应发生率为8%,对照组为6%,两组差异无统计学意义(P>0.05)。结论针对婴幼儿急性喘息性支气管炎患儿采取口服孟鲁司特治疗,可有效提高患儿雾化吸入治疗的效果,更加有效地促使其临床症状得到缓解,且不良反应较少,安全性可靠。

Objective To study and explore the clinical effect of oral administration of Montelukast in the treatment of atomization and inhalation of infantile asthmatic bronchitis.Methods 100 children with asthmatic asthmatic bronchitis who enrolled in our pediatric outpatient department from January 2013 to October 2016 were selected as research object,the subjects were randomly divided into two groups by single blind random grouping method,50 cases in the control group was treated with inhalation of Budesonide and Salbutamol,50 cases in the observation group was treated with Montelukast oral treatment which based on the control group,the asthmatic bronchitis clinical treatment effect,symptom relief time,outpatient treatment time and the incidence of adverse reactions were compared between two groups.Results The total effective rate of treatment in the observation group （96%） was significantly higher than that in the c（mtrol group （80%）,the difference was statistically significant （P〈0.05）;symptom relief time of respiration [（4.10±1.85） d],cou＇gh [（2.01±0.96） d], wheeze [（4.59±1.94） d] and outpatient treatment time [（6.13±1.72） d] of the observation group was sig- nificantly shorter than that in the control group [（6.73±2.42）,（3.36±1.28）,（7.23±2.60）,（8.49±2.38） d] respectively,the dif ference was statistically significant （P〈0.05）;the incidence of adverse reactions was 8% in the observation group and 6% in the control group, there was no significant difference between the two groups （P〉0.05）.Conclusion In the treatment of children with asthmatic bronchitis,oral Montelukast treatment can effectively improve the effect of children inhalation therapy,promote its clinical symptoms more effectively,and with less adverse reactions,the safety is reliable.